company? Let’s change
that.
Don't see your company?
Create a company profileHazel Technologies develops products that extend the shelf life of produce. Our customers include some of the largest produce growers in the world.
Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle disease. We are applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve efficacy and safety of gene therapy and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.
eTeki is where the world goes to qualify talent. Our award winning technical interviews-as-a-service platform enables organizations across the globe hire the best tech talent, fast. eTeki is poised to disrupt the way IT candidates are hired by giving any company the ability to screen large numbers of tech talent quickly. Unlike conventional video interviewing tools available today, eTeki is powered by a network of trained and certified IT specialists offering services to assess each candidate’s technical skills in real time. Our network of over 5000 expert interviewers have expertise in every stack and provide an unbiased assessment of technical skills and behavioral fit, with an extensive candidate report and video in 24 hours or less. Full and self service options are available. eTeki lets organizations save money, reduce bad hires, and hire the best talent for the job. eTeki's leadership team has over 100 years combined experience with marketplaces, tech screening and hiring. Our mission is to supply the world with interviews-as-a-service to scale and optimize technical hiring.
MSDx is a personalized medicine company developing blood testing products for brain diseases.
Here at CRISPR QC, we empower scientists using CRISPR to solve the world’s great challenges by providing the key cornerstones of information and insight fundamental to realizing the full potential of CRISPR.
We're on a mission to futureproof the joy of food, starting with the joy of pig!
We focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics.
Mendel is the technology platform hub for Koch Biological Solutions, a global leader in delivering targeted, science-based biological products to improve crop productivity. In 2019, KBIO became part of Plant Response, Inc.
We are a science and material innovation company rethinking biology and reimagining the world. A World Economic Forum Tech Pioneer, we partner with nature to create never-before imagined materials and products across industries – from agriculture to electronics, consumer care to pharmaceuticals, and more. Our company creates sustainable materials that are in use today, delivering value for Fortune 1000 companies with over $1 billion worth of products using Zymergen microbial innovations sold to date. At Zymergen we make tomorrow.
High Quality Pharmaceuticals from Yeast.
At RedVault, we are committed to creating innovative technologies to advance genomic medicine.
NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology. NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities. For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond.
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet
What is exciting about the area we work in Epigenomics is the systematic analysis of the global state of gene expression not attributable to mutational changes across the entire genome. Epigenetic mechanisms are affected by external factors including development in utero and in childhood, environmental chemicals, drugs and pharmaceuticals, aging, and diet. Changes to the epigenetic landscape can have a profound impact on health and disease. Precise mapping and measurement of the epigenetic landscape offers the promise of predictive biomarkers of disease development, even before changes in gene expression have taken place. Epigenomics is the “OME” connecting Genomics to Transcriptomics and Proteomics allowing a Multiomics approach to disease research which will result in a higher yield of data that can be aggregated and analyzed to become actionable information. What does Active Motif offer Epigenetic methods and approaches require the use of high-quality antibodies and enzymes that have undergone strict validation criteria. This allows the development of robust assays for use in mechanistic studies, translational medicine, drug discovery and diagnostics. Active Motif’s Product Development Program takes emerging novel techniques, and develops them into innovative products that allow researchers to perform the assays in their own labs as well as feeding into their end to end services pipeline. Active Motif is building a platform based on their patented transposase based technologies to simplify the interrogation of chromatin, the dynamics of histone modifications, chromatin remodeling, DNA methylation, transcription factor binding, as well as short and long range gene regulation by non-coding regulatory regions. Our bioinformatics platform can take the data generated by these techniques and provide powerful insights into the epigenetic changes occurring in disease or in response to drugs.
Hospital Corporation of America (HCA) provides healthcare services in locally managed facilities in 20 states in the U.S. and England.
Geltor is the biodesign company that audaciously imagines and deeply explores all the possibilities that the tree of life has to offer. With customer benefit at the fore of each step of the creative process, Geltor has created the largest selection of designer proteins that are crafted with unparalleled biocompatibility and functionality. These proteins are 100% animal- and GMO-free, globally scalable, and sustainably cultivated. Geltor’s products are the result of endless curiosity and ceaseless optimization, clinically demonstrated for high performance.
An innovative biotechnology company focused on providing its worldwide customers the best-in-class raw materials and components for superior research and product development. We develop and manufacture stem cell products, cell culture products, and cGMP tools and technologies for the cell therapy industry.
Essen BioScience is a world leader in the field of cell-based in vitro assays and instrumentation.
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
We accelerate technology innovation in precision diagnostics to enable diseases to be detected, treated and cured earlier for better outcomes with lower costs.